KRAS and cancer: Usually, shared mutations involved well-characterised cancer drivers (e.g., TP53, APC, KRAS, BRAF) and have higher allele frequencies (compared to alterations which are exclusive of a single component), suggesting their occurrence in the earlier stages of the development of MiNENs [29,58,79,93,97].